(4) Cameron N and Cotter M. Potential benefits of epoetin delta in diabetic rats: focus on neuropathy. Abstract accepted at American Society of Nephrology Renal Week, San Francisco, CA, USA. 2-5 November 2007.
(5) Pratt, R. Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis. Poster presented at American Society of Nephrology Renal Week, San Diego, CA, USA; 14-19 November 2006
(6) Deicher R and Hörl W. Differentiating factors between erythropoiesis-stimulating agents. Drugs 2004; 64(5): 499-509.
(7) DYNEPO Summary of Product Characteristics. Shire Pharmaceuticals. April 2007.
For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact: Investor Relations: Cléa Rosenfeld +44-1256-894-160, Media Shire: Jessica Mann, +44-1256-894-280, Media PR agents for DYNEPO: Resolute Communications, May Baccari, +44-207-357-8187, Media PR agents for DYNEPO: Resolute Communications, Kirsty Mearns, +44-207-357-8187
